Repare Therapeutics Entered into Worldwide License Agreement with Roche
Jun 2, 2022 By MarketDepth
Repare Therapeutics Inc. (Nasdaq: RPTX) today announced that it had entered into a worldwide license and collaboration agreement with Roche.
Shares Up Premarket
Shares of Repare Therapeutics Inc. (Nasdaq: RPTX) gained over 23% during the premarket trading session.
Collaboration for Development
The two companies will now collaborate on the development and commercialization of camonsertib ( RP-3500), a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene.
“Camonsertib has the potential to help cancer patients across numerous solid tumors as a monotherapy and possibly in combination with other agents.
Kim Seth, Ph.D., EVP and Head of Business & Corporate Development at Repare
Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies and receive a $125 million upfront payment. Furthermore, the company is eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones.
“Given the encouraging data Repare has generated for camonsertib as a potentially best-in-class ATR inhibitor with a promising tolerability profile and patient selection insights in areas of high unmet medical need, and Roche’s leading global footprint and unique expertise in precision oncology, we are confident that Roche is the ideal partner for us to drive the broad global development and commercialization of camonsertib.”
Kim Seth, Ph.D., EVP and Head of Business & Corporate Development at Repare
